RxDoctor Payments Data

Douglas Saunders, MD

Internal Medicine · Cincinnati, OHNPI 1760473532

Payments from drug & device makers

$1,628in general payments, 2019–2025

Across 116 payments — averaging $14.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$202
  • Johnson & Johnson$195
  • Novo Nordisk$171
  • AstraZeneca$157
  • Amgen$151
  • Abbott$144
  • plus $608 from 12 others

What the payments were for

  • Food & beverage$1,61399%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,628 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$96,877
Medicare patients
318
Services billed
2,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$118,911
TrulicityDulaglutide59$84,322
OzempicSemaglutide70$80,727
FarxigaDapagliflozin Propanediol59$57,280
JardianceEmpagliflozin53$54,404
JanuviaSitagliptin Phosphate36$45,203
MounjaroTirzepatide42$43,481
XareltoRivaroxaban29$39,637
EntrestoSacubitril/Valsartan12$20,969
Spiriva HandihalerTiotropium Bromide13$20,172
Praluent PenAlirocumab18$19,994
Breo ElliptaFluticasone/Vilanterol20$14,421
MyrbetriqMirabegron11$13,723
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$11,413
SymbicortBudesonide/Formoterol Fumarate28$11,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$87$127,803101 claims
PfizerEliquis$142$118,911123 claims
Novo NordiskOzempic$171$80,72770 claims
AstraZenecaFarxiga, Symbicort$157$68,30887 claims
Boehringer IngelheimJardiance$49$54,40453 claims
Johnson & JohnsonXarelto$195$39,63729 claims
GSKBreo Ellipta, Trelegy Ellipta$64$22,77331 claims
NovartisEntresto$202$20,96912 claims
Astellas Pharma US IncMyrbetriq$54$13,72311 claims
AbbVieSynthroid$28$5,67276 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →